Everlab, the AI-powered health platform reimagining preventive care, announced a US$10 million (AU$15 million) seed round led by global growth equity firm Left Lane Capital. The funding will accelerate Everlab’s international expansion, fuel the development of its proprietary AI healthtech platform, and support the rollout of a deeply integrated product ecosystem designed to deliver lifelong, proactive care.

Chronic disease is responsible for over 70% of global deaths, yet most healthcare systems remain reactive, designed to treat illness only after it appears. While early detection and personalized intervention can save lives, they remain inaccessible for most.

Everlab addresses this gap with a tiered membership model that combines advanced diagnostics, digital-first doctor consultations, and intelligent health insights to deliver personalized prevention at scale. Members have access to comprehensive screening services, including advanced blood testing, whole-body MRIs, DEXA scans, VO2 max, ECG, isometric strength, continuous glucose monitoring, food journal analysis, and CT coronary angiograms paired with continuous support and personalized prevention plans. The flagship Protocol membership delivers year-round diagnostics and clinically guided interventions, all at a fraction of the cost of traditional care models.

At the core of Everlab’s offering is its proprietary, full-stack clinical platform: a suite of AI agents that ingest, analyze, and interpret complex health data. These agents automate clinical summaries, identify early risk markers, and recommend personalized next steps, freeing physicians from administrative overhead and enabling earlier, more precise interventions. Through integrations with national pathology and radiology networks, Everlab maintains a real-time, longitudinal health record for every member, deeply embedding the platform within the existing healthcare system.

“We believe everyone deserves access to world-class preventive care,” said Marc Hermann, Founder and CEO of Everlab. “By combining AI with the knowledge of leading clinicians, we’ve built a new kind of health platform designed to deliver smarter, earlier care to millions.”

Everlab’s early momentum has been significant. With tens of thousands of customers on its waitlist and growing demand across both consumer and enterprise markets, the company is on track for 20x growth this year. Its go-to-market model positions Everlab as the leading provider of high-quality, prevention-focused care.

To date, Everlab has processed over 1,000,000 biomarkers through full-body health testing. Alarmingly, one in four test results are abnormal, and for 2.5% of members, findings have been life-changing—uncovering serious conditions such as blocked arteries, gastrointestinal tumors, early-stage cancers, and congenital brain abnormalities.

Beyond diagnostics, Everlab provides data-driven, personalized interventions tailored to each member’s risk profile and health goals. Results from a meta-analysis of members retested at the platform’s built-in six-month mark show that over one-third of modifiable biomarkers improved, demonstrating the tangible health impact of Everlab’s model.

“Preventive care has always been a medical ideal but rarely a commercial reality,” said Laura Sillman, Principal at Left Lane Capital. “Everlab has built a product and model that makes it scalable, combining clinical depth with software leverage and operational precision. We’re excited to support them as they build a category-defining platform.”

With this new round of funding, Everlab will continue to grow its clinic network, expand its engineering and clinical teams, and advance its AI-powered infrastructure—laying the foundation for a global, scalable system of preventive healthcare.